bullish
Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down
8.2k Views10 Aug 2022 15:17
SUMMARY
- Pharmaessentia Corp (6446 TT) is on a robust growth path following the U.S. launch of its key drug Besremi for polycythemia vera (PV) in December 2021.
- The company has reported July net revenue of NT$348.5 million, an increase of 937% and 26% from July 2021 and June 2022, respectively.
- Besremi has further label expansion opportunity as the drug is undergoing clinical trials for additional indications including essential thrombocythemia (ET), myelofibrosis, and chronic hepatitis.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Besremi Revenue Is Recovering; Fund Raising Through GDS Completed21 Jul 2023
- Pharmaessentia Corp (6446 TT): Besremi Starts 2023 on Strong Note; Geography Expansion Continues15 Feb 2023
- Pharmaessentia Corp (6446 TT): Riding High Aided by Continued Strong Uptake of Besremi in US14 Nov 2022
- Pharmaessentia Corp (6446 TT): Key Drug Is Advancing Commercialization Globally05 May 2022
- Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow25 Nov 2021
x